Latest news with #benralizumab
Globe and Mail
17-07-2025
- Business
- Globe and Mail
AstraZeneca's Real-Life Study on Benralizumab: Market Implications and Progress
AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Study Overview: AstraZeneca is conducting a non-interventional, prospective study titled A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life. The study aims to assess asthma control, health-related quality of life, lung function, and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in Germany. This research is significant as it evaluates real-life outcomes of benralizumab, providing insights into its effectiveness in routine clinical practice. Intervention/Treatment: The study focuses on benralizumab, a monoclonal antibody used to treat severe eosinophilic asthma. It aims to improve asthma control and quality of life by targeting and reducing eosinophils, a type of white blood cell involved in asthma inflammation. Study Design: This is an observational cohort study with a prospective time perspective. It involves a single-arm, multicenter approach where patients' asthma control and quality of life are monitored using various questionnaires and diaries over a 52-week period. Study Timeline: The study began on July 25, 2024, with its primary completion and estimated completion dates yet to be announced. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study's progress and anticipating future findings. Market Implications: The ongoing study could influence AstraZeneca's stock performance by showcasing benralizumab's real-world effectiveness, potentially boosting investor confidence. As the asthma treatment market is competitive, positive results may enhance AstraZeneca's position against competitors, impacting market dynamics and investor sentiment. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Medscape
06-05-2025
- Health
- Medscape
Benralizumab Maintains Remission in Asthma in Some, Not All
Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive patients than in biologic-experienced patients. METHODOLOGY: Researchers conducted a real-world study to evaluate if long-term remission was viable among adult patients with SEA (mean age at the index date, 55.2 years; 58.7% women) who received benralizumab for up to 96 weeks between 2018 and 2023. Of the 1070 patients included, 662 were biologic naive and 404 were biologic experienced; 55% received maintenance oral corticosteroids at baseline. The major outcome was clinical remission (defined as a composite of the absence of exacerbations, no use of maintenance oral corticosteroids, and well-controlled asthma) at weeks 0, 48, and 96. The association between baseline characteristics and the status of clinical remission at weeks 48 and 96 was also determined. TAKEAWAY: Clinical remission was achieved in 0.4% of patients at baseline, in 39.0% at week 48, and in 31.0% at week 96, with biologic-naive patients showing higher remission rates than biologic-experienced patients (36.0% vs 23.0%). Exacerbation-free status was achieved in 3.3% of patients at baseline, in 72.0% at week 48, and in 60.0% at week 96, with a greater number of biologic-naive patients being exacerbation-free than biologic-experienced ones (67.0% vs 55.0%). Overall, the proportion of patients not using maintenance oral corticosteroids increased from 65% at baseline to 76% at weeks 48 and 96. A lower dose of maintenance oral corticosteroids, lower body mass index, and higher blood eosinophil count at baseline were associated with achieving remission at week 96. IN PRACTICE: 'Outcomes were maintained irrespective of previous biologic use and key baseline characteristics that clinicians typically consider in their therapeutic decision-making. Patients with lower disease burden were more likely to achieve clinical remission, reinforcing the importance of early treatment intervention,' the authors wrote. SOURCE: This study was led by Girolamo Pelaia, MD, Università Magna Graecia in Catanzaro, Italy. It was published online on April 19, 2025, in CHEST . LIMITATIONS: This study lacked a control arm. The limited availability of data on lung function restricted its inclusion in the remission composite. The COVID-19 pandemic overlapped with the period of data collection, potentially affecting outcomes. DISCLOSURES: This study was supported by AstraZeneca. Several authors reported being employees of and owning stock in AstraZeneca. Some others reported having other ties with AstraZeneca and various sources.
